GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cochlear Ltd (OTCPK:CHEOY) » Definitions » Tax Expense

CHEOY (Cochlear) Tax Expense : $85 Mil (TTM As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Cochlear Tax Expense?

Cochlear's tax expense for the months ended in Jun. 2024 was $39 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was $85 Mil.


Cochlear Tax Expense Historical Data

The historical data trend for Cochlear's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cochlear Tax Expense Chart

Cochlear Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.64 29.97 73.58 64.43 84.99

Cochlear Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.29 31.11 33.49 45.92 39.44

Cochlear Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cochlear  (OTCPK:CHEOY) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Cochlear Tax Expense Related Terms

Thank you for viewing the detailed overview of Cochlear's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cochlear Business Description

Traded in Other Exchanges
Address
1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.

Cochlear Headlines

From GuruFocus

Cochlear Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024

Cochlear Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024

Half Year 2024 Cochlear Ltd Earnings Call Transcript

By GuruFocus Research 02-28-2024

Full Year 2022 Cochlear Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Full Year 2021 Cochlear Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Full Year 2024 Cochlear Ltd Earnings Call Transcript

By GuruFocus News 10-09-2024

Cochlear Ltd Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024

Cochlear Ltd Capital Markets Day Transcript

By GuruFocus Research 02-13-2024

Full Year 2019 Cochlear Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024